The present invention relates to a compound for treatment of a disease or disorder involving inflammation in the myocardium, such as for example myocardial infarction due to myocardial ischemia, myocardial infarction due to myocardial ischemia/reperfusion, myocarditis, sepsis, sepsis-induced myocardial inflammation, and septic cardiomyopathy. The present invention further relates to treatment of a disease or disorder involving inflammation in the myocardium by administration of said compound during the acute phase of said disease or disorder.

The present invention relates to a compound for treatment of a disease or disorder involving inflammation in the myocardium, such as for example myocardial infarction due to myocardial ischemia, myocardial infarction due to myocardial ischemia/reperfusion, myocarditis, sepsis, sepsis-induced myocardial inflammation, and septic cardiomyopathy. The present invention further relates to treatment of a disease or disorder involving inflammation in the myocardium by administration of said compound during the acute phase of said disease or disorder.

A method is described in which treatment is carried out with compounds of tetrahydropyridoethers that are administered in form of a medication to treat AMD and to remove lipofuscin from a patient's eye.

A method is described in which treatment is carried out with compounds of tetrahydropyridoethers that are administered in form of a medication to treat AMD and to remove lipofuscin from a patient's eye.

The invention relates to ocular, intranasal, oromucosal or pulmonary administration of (R)—N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) for the treatment of diseases and conditions where, for example, inotropic, vasodilatory or calcium sensitizing effects are desired. The invention also relates to pharmaceutical dosage forms adapted for ocular, intranasal, oromucosal or pulmonary administration comprising (R)—N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) as an active ingredient.

The invention relates to ocular, intranasal, oromucosal or pulmonary administration of (R)—N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) for the treatment of diseases and conditions where, for example, inotropic, vasodilatory or calcium sensitizing effects are desired. The invention also relates to pharmaceutical dosage forms adapted for ocular, intranasal, oromucosal or pulmonary administration comprising (R)—N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) as an active ingredient.

The invention relates to ocular, intranasal, oromucosal or pulmonary administration of (R)—N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) for the treatment of diseases and conditions where, for example, inotropic, vasodilatory or calcium sensitizing effects are desired. The invention also relates to pharmaceutical dosage forms adapted for ocular, intranasal, oromucosal or pulmonary administration comprising (R)—N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) as an active ingredient.

The present invention relates to compositions, methods, uses and kits for the treatment of renal cystogenesis. In particular, the compositions, methods, uses and kits are particularly useful, but not limited to, the treatment or prevention of Polycystic Kidney Disease. In one aspect, the prevent invention provides a method of minimising or delaying renal cystogenesis in a subject in need thereof, the method comprising inhibiting AKT in the subject, or reducing the level of Aurora kinase in the subject, thereby minimising or delaying renal cystogenesis.

Disclosed herein are methods and compositions for the treatment of movement disorders including neuromuscular disorders, muscular injuries, and spasticity-associated conditions. Methods of treatment include reducing skeletal muscle contractions to reduce muscle damage by inhibiting skeletal muscle myosin II.

Disclosed herein are methods and compositions for the treatment of movement disorders including neuromuscular disorders, muscular injuries, and spasticity-associated conditions. Methods of treatment include reducing skeletal muscle contractions to reduce muscle damage by inhibiting skeletal muscle myosin II.